RajshekharChakrabortyMD

PubMed

• High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy.
  George S Mellgard, Divaya Bhutani, Markus Y Mapara, Mathew S Maurer, Jai Radhakrishnan, Suzanne Lentzsch, Rajshekhar Chakraborty> ;Bone Marrow Transplantation. 2024 May 9
• The Clinical Trials Landscape in Immunoglobulin Light Chain Amyloidosis: A Systematic Review.
  Darshi Shah, Catherine Luo, Veer Shah, Edward Robert Scheffer Cliff, Ramya Ramachandran, Vaishali Sanchorawala, Suzanne Lentzsch, Rajshekhar Chakraborty> ;Blood Advances. 2024 May 2
• Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.
  Darshi Shah, Charalampos Charalampous, Shaji Kumar, Rajshekhar Chakraborty> ;Annals of Hematology. 2024 Apr 17
• Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
  Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan...> ;Blood Cancer Journal. 2024 Mar 5
• Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study.
  Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke,...> ;Blood Cancer Journal. 2024 Mar 5
• Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma.
  Molly Gilligan, Edward R Scheffer Cliff, Ghulam R Mohyuddin, Andrew Eisenberger, George Mellgard, Divaya Bhutani, Suzanne Lentzsch, Rajshekhar Chakraborty> ;Hemasphere. 2024 Mar 1
• Clinical implications and insights from patient-reported outcome data in KarMMa-3.
  Chakraborty, R.> ;The Lancet. Haematology. 2024 Mar 1
• Dietary interventions in cancer: a systematic review of all randomized controlled trials.
  Abdul Khader, A., Smith, C., Cliff, E., Booth, C., Rd, E., Lee-Smith, W., Goodman, A., Mohyuddin, G., Ilerhunmwuwa, N., Aziz, M., Chakraborty, R.> ;Journal of the National Cancer Institute. 2024 Mar 1
• 1 citations
  Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review.
  Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy Schmidt, Rafael Fonseca, Rajshekhar Chakraborty, Kelly Ann Koehn, Meera Mohan, Hira Mian, Luciano J Cos...> ;Blood Cancer Journal. 2024 Jan 25
• 1 citations
  Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study.
  Maurer, M., Chakraborty, R., Mapara, M., Reshef, R., Radhakrishnan, J., Lentzsch, S., Bhutani, D.> ;American Journal of Hematology. 2024 Mar 1
• Use of subjective minimizing language at hematology and oncology conferences: A systematic review.
  Abdel-Azez Abusamak, Mohammad Abusamak, Mohammed Al-Abbadi, Abdallah Rayyan, Omar Oran, Ghulam Rehman Mohyuddin, Amar H Kelkar, Aaron M Goodman, Rajshekhar Chakraborty...> ;Journal of Cancer Policy. 2024 Mar 1
• 1 citations
  Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis.
  Rajshekhar Chakraborty, Mathew S Maurer, Meera Mohan, Suzanne Lentzsch, Anita D'Souza, Bhutani, D.> ;Blood Cancer Journal. 2023 Nov 27
• Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review.
  Jawad Alrawabdeh, Marah Alzu'bi, Muntaser Alzyoud, Nada Odeh, Yazan Hamadneh, Hira Mian, Ghulam Rehman Mohyuddin, Amar H Kelkar, Aaron M Goodman, Rajshekhar Chakrabort...> ;JNCI Cancer Spectrum. 2023 Oct 31
• Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma.
  Mimi Najjar, John McCarron, Edward R Scheffer Cliff, Katherine Berger, David P Steensma, Samer Al Hadidi, Rajshekhar Chakraborty, Aaron Goodman, Eric Anto, Tom Greene,...> ;JAMA Network Open. 2023 Nov 1
• 4 citations
  Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey.
  Mohyuddin, G., Cliff, E., Derman, B., Chakraborty, R.> ;Eclinicalmedicine. 2023 Nov 1
• Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies.
  Rajshekhar Chakraborty, Paolo Milani, Giovanni Palladini, Morie Gertz> ;The Lancet. Haematology. 2023 Nov 1
• 10 citations
  The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
  Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra,...> ;Haematologica. 2024 Mar 1
• 1 citations
  Follow up duration of phase III Multiple Myeloma Clinical Trials: A systematic review.
  Mohammad O Ali, Hafez M Abdullah, Khaldun Obeidat, Rajshekhar Chakraborty, Samer Al Hadidi> ;Ejhaem. 2023 Aug 1
• 1 citations
  Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study.
  Arleigh McCurdy, Hsien Seow, Gregory P Pond, Anastasia Gayowsky, Rajshekhar Chakraborty, Alissa Visram, Rayan Kaedbey, Anita D'Souza, Ghulam Rehman Mohyuddin, Tanya M ...> ;Haematologica. 2023 Dec 1
• Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review.
  Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron Goodman, Rajshekhar Chakraborty, Douglas Sborov, Samuel Rubinstein, Ghulam Rehman Mohyuddin> ;European Journal of Haematology. 2023 Sep 1
• 13 citations
  Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.
  Meera Mohan, Rajshekhar Chakraborty, Susan Bal, Anoma Nellore, Muhamed Baljevic, Anita D'Souza, Peter G Pappas, Jesus G Berdeja, Natalie Callander, Luciano J Costa> ;British Journal of Haematology. 2023 Dec 1
• Intent Matters: Real-World Applicability of Idecabtagene Vicleucel Usage in the United States.
  Rajshekhar Chakraborty, Samer Al Hadidi> ;Journal of Clinical Oncology. 2023 Jul 10
• 2 citations
  Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis.
  Agrima Mian, Syed Arsalan Ahmed Naqvi, Ahsan Ayaz, Muhammad Husnain, Mohammed A Aljama, Ghulam Rehman Mohyuddin, Kelly Koehn, Meera Mohan, Rajshekhar Chakraborty, Irba...> ;Leukemia Research. 2023 Aug 1
• 1 citations
  How do we image patients with multiple myeloma and precursor states?
  Rajshekhar Chakraborty, Jens Hillengass, Suzanne Lentzsch> ;British Journal of Haematology. 2023 Nov 1
• 3 citations
  Is aggressive treatment of smoldering myeloma the path to curing myeloma?
  Rajshekhar Chakraborty, Samer Al Hadidi, Edward R Scheffer Cliff, Ghulam Rehman Mohyuddin> ;Blood Advances. 2023 Aug 8
• Join now to see all

Abstracts/Posters

• Risk of Serious Infections with Carfilzomib in Patients with Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
  Rajshekhar Chakraborty, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Lectures

• Venous thromboembolism risk with contemporary lenalidomide-based regimes for multiple myeloma: A systematic review and meta-analysis. 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
• Depth of Pre-Treatment Immunoparesis Is an Important Prognostic Factor for Survival in Relapsed Multiple Myeloma 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019